- with readers working within the Automotive and Insurance industries
The China National Intellectual Property Administration (CNIPA) administers more than 7,000 patent invalidation cases annually – an enormous caseload compared to that of the European and United States patent offices. In the second article in a two-part series for Managing IP, Marshall Gerstein Partner Sandip Patel is joined by Dr. Siqi Wang and Xiaoli Liu, Beijing-based patent attorneys at Spruson & Ferguson, to explore how Chinese courts adjudicate appeals of patent invalidation decisions issued by CNIPA.
Building on the procedural framework outlined in the first installment, the authors focus on representative cases that illustrate how courts evaluate both procedural compliance and substantive technical issues on appeal. The article highlights key principles that often shape outcomes, including the “principle of hearing” and the “principle of request,” and explains how courts assess inventiveness, prior art combinations, and the admissibility of post-filing data.
The authors demonstrate how procedural missteps, such as failing to provide adequate notice or opportunity to respond, can result in decisions being overturned. They also examine how courts approach complex technical questions, particularly in pharmaceutical and chemical patent disputes, where small distinctions in structure or disclosure can be determinative.
The article provides practical insight for companies navigating patent challenges in China, emphasizing the importance of both procedural rigor and technical precision in invalidation and appeal strategies. It also underscores the broader role of judicial review in ensuring fairness and consistency in China’s patent system.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.
[View Source]